FTRE logo

Fortrea Holdings Inc.

FTRE
Healthcare|Biotechnology|US
$21.96
+1.50 (+7.33%)
Cash / Share
$2.31

About

Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.

Stock Price

+99.3%(1Y)
1M
+7.8%
3M
+19.2%
6M
+42.3%
YTD
+27.3%
1Y
+96.4%
3Y
-22.9%
5Y
-31.4%

Pipeline Summary

35 total trials
10
Phase 1
9
Phase 2
11
Phase 3
2
Phase 4
Completed: 11Active: 8Recruiting: 12Not Yet Recruiting: 2Terminated: 1Unknown: 1

Active Trials (20)

Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an AI Software During AF Ablation
NCT06083012Atrial Fibrillation
Active
Enrollment: 186 participants
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia
Phase 3Recruiting
Enrollment: 264 participants
A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395
NCT07820891Healthy Adult Participants
Phase 1Recruiting
Enrollment: 24 participants
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
NCT07109219B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 1Phase 2Recruiting
Enrollment: 83 participants
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779Severe Asthma
Phase 3Active
Enrollment: 310 participants

Key Facts

Market Cap$2.08B
Employees14,300 (-8% YoY)
CEOAnshul Thakral
IPO DateJun 20, 2023
Beta1.86
52-Week Range$8.55 – $26.16
Avg Volume1,604,058
ExchangeNASDAQ

Ownership

Float99.5%
Shares Outstanding94.6M

Recent Insider Trades

Knoblauch Jason FredrickAWARD
Sep 10, 2026144,434 shares
Russell Carrie ElizabethOPTION EX.
Sep 8, 2026850 shares
Russell Carrie ElizabethOPTION EX.
Sep 8, 2026850 shares
Russell Carrie ElizabethSELL
Sep 9, 2026246 shares @ $16.85
Morais Mark A.OPTION EX.
Sep 8, 20267,157 shares

Peers

CERTCertara, Inc.
$1.84B
MEDPMedpace Holdings, Inc.
$18.27B
Data last updated: Nov 9, 2026, 04:11 AM